Phaseline

Companies › Santen Pharmaceutical

Santen Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 3; Ophthalmology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DE-117B Eye Drops
Prostaglandin F (FP) receptor agonist
PTGFRPhase 3Open Angle Glaucoma–
STN1013800 ophthalmic solution–Phase 3Blepharoptosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06683651STN1013800 ophthalmic solutionPhase 3BlepharoptosisOphthalmologyJun 2026
NCT06666855DE-117B Eye DropsPhase 3Open Angle GlaucomaOphthalmologyAug 2026

From the company's SEC filings

Complete response letters from FDA

Targets

PTGFR (1)

Companies with the same targets

SpyGlass Pharma Glaukos YS Life Science Triple Hair

Companies built like this

YS Life Science SpyGlass Pharma ReGenTree Ocus Innovation Ireland Ocumension Therapeutics (Suzhou)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.